Drugs / Adbelimumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06538935 | Jan 2025 → Dec 2026 expected | hepatocellular carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06576973 | Aug 2024 → Dec 2026 expected | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adbelimumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06538935 ↗ |
| Action | Inhibit | “Adbelimumab (an Anti-PD-L1 Inhibitor)” NCT06538935 ↗ |
| Route | Intravenous | “adbelimumab：1200mg iv d1 q3w” NCT06538935 ↗ |